One Drug Wins and Another Fails for Long COVID Fatigue (fluvoxamine, metformin) - Medpage Today

ahimsa

ahimsa

Senior Member (Voting Rights)
www.medpagetoday.com

One Drug Wins and Another Fails for Long COVID Fatigue

A previous trial of the two drugs showed the opposite effect for reducing the risk of long COVID
www.medpagetoday.com www.medpagetoday.com

MedPage Today said:
Key Takeaways
  • Fluvoxamine and metformin have anti-inflammatory and immunomodulatory properties that have led researchers to test their ability to prevent and treat long COVID and its symptoms.
  • In a randomized trial, fluvoxamine led to a significant reduction in fatigue as measured by the Fatigue Severity Scale compared with placebo at day 60, with a 99% posterior probability of superiority.
  • Among participants receiving metformin, fatigue scores at 60 days were not significantly different versus placebo.
Click to expand...
The antidepressant fluvoxamine delivered clinically relevant reductions in long COVID fatigue, but the diabetes drug metformin didn't outdo placebo, according to the randomized REVIVE-TOGETHER trial.

Among 399 adults with long COVID, those receiving fluvoxamine had a significant reduction in fatigue as measured by the Fatigue Severity Scale (FSS) compared with placebo at day 60 (mean difference - 0.43, 95% credible interval [CrI] -0.80 to -0.07), with a 99% posterior probability of superiority, reported Jamie Forrest, PhD, MPH, of the University of British Columbia in Vancouver, and colleagues.

This effect was sustained at day 90 (mean difference -0.58, 95% CrI - 0.98 to -0.16), with a 99.7% probability of superiority.
Click to expand...
There's a lot more detail in the article. I hope someone on here can look at it and see whether this looks useful.

Link to paper (Annals of Internal Medicine):

 
You must log in or register to reply here.
Back
Top Bottom